Hims & Hers Health is trying to make weight loss cheaper—and turn telehealth into a front door
TL;DR
Quick Summary
- On February 5, 2026, Hims announced a compounded semaglutide pill for weight loss with intro pricing starting at $49 for the first month (then standard $99/month, per company terms).
- This is less about “beating” big pharma and more about owning the onboarding experience—cost + convenience + subscription follow-through.
- Hims’ scale heading into 2026 matters: $586.0M revenue and 2.4M subscribers in Q1 2025; nearly $600M revenue and almost 2.5M subscribers by Q3 2025 (reported November 3, 2025).
You've reached your free daily article limit (1/1).
Create a free account to get unlimited access to all articles, market insights, and more.
Register for FreeAlready have an account? Sign in
Disclaimer: KAHROS is a financial media and technology company. The Services, including any AI-generated content and articles, are for informational purposes only and do not constitute financial, legal, tax, or investment advice, nor an offer or solicitation to buy or sell any securities. Market information may be time-sensitive, incomplete, or subject to change without notice. We are not a registered broker-dealer or investment advisor. Please refer to our Terms of Service for more details.
Disclaimer: KAHROS is a financial media and technology company. The Services, including any AI-generated content and articles, are for informational purposes only and do not constitute financial, legal, tax, or investment advice, nor an offer or solicitation to buy or sell any securities. Market information may be time-sensitive, incomplete, or subject to change without notice. We are not a registered broker-dealer or investment advisor. Please refer to our Terms of Service for more details.
